PMID- 25817540
OWN - NLM
STAT- MEDLINE
DCOM- 20150803
LR  - 20150417
IS  - 1873-5835 (Electronic)
IS  - 0145-2126 (Linking)
VI  - 39
IP  - 5
DP  - 2015 May
TI  - The clinical characteristics and prognosis of IGH deletion in multiple myeloma.
PG  - 515-9
LID - S0145-2126(15)00067-3 [pii]
LID - 10.1016/j.leukres.2015.02.010 [doi]
AB  - OBJECTIVE: To analyze the frequency, clinical characteristics, and prognosis of 
      IGH deletion in multiple myeloma (MM). METHODS: A total of 310 consecutive 
      patients with multiple myeloma were analyzed. Among them 251 patients were newly 
      diagnosed and 59 patients were previously treated, fluorescence in situ 
      hybridization (FISH) with IGH break apart probes were done for each case. 
      Patterns of IGH deletion, response rate, overall survival, and progression free 
      survival were analyzed. RESULTS: Several patterns of IGH deletion were 
      identified, including monoallelic deletion of whole locus of IGH, monoallelic 
      deletion of 3' IGH, monoallelic deletion of 5' IGH, biallelic deletion of 3' IGH 
      deletion, and complicated deletions with various types. The incidence rate of IGH 
      deletion was 22.7% (57/251) in newly diagnosed patients and 27.2% (16/59) in 
      previously treated patients, no significant difference was found between the two 
      groups (p=0.375). IGH deletion was associated with kappa light chain M component 
      (p<0.001), 13q deletion (p=0.006), and absence of t(4; 14)(p=0.033). In the cases 
      with 13q deletion, the frequency of IGH deletion is 3.5% (1/28) in patients with 
      t(4;14) and 40.5% (32/79) in patients without t(4;14), significant difference was 
      found (p=0.006). We further analyzed the response rates of patients with IGH 
      deletion who received a uniform induction regimen of PAD composing of bortezomib, 
      epirubicin, and dexamethasone. Overall response rate (ORR) in patients with IGH 
      deletion was better than that in patients without IGH deletion (87.5 vs. 73.6%, 
      p<0.001), while no significant difference was found in survival analysis, either 
      OS or PFS (p=0.158 and p=0.177, respectively). CONCLUSION: IGH deletion is 
      frequent in multiple myeloma, the incidence rate was higher in patients with 13q 
      deletion and without t(4;14). Patients with IGH deletion had better ORR to PAD 
      induction therapy, while it has no influence on the prognosis of multiple 
      myeloma.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - He, Haiyan
AU  - He H
AD  - Myeloma and Lymphoma Center, Department of Hematology, Changzheng Hospital, 
      Shanghai, China.
FAU - Fu, Weijun
AU  - Fu W
AD  - Myeloma and Lymphoma Center, Department of Hematology, Changzheng Hospital, 
      Shanghai, China.
FAU - Jiang, Hua
AU  - Jiang H
AD  - Myeloma and Lymphoma Center, Department of Hematology, Changzheng Hospital, 
      Shanghai, China.
FAU - Du, Juan
AU  - Du J
AD  - Myeloma and Lymphoma Center, Department of Hematology, Changzheng Hospital, 
      Shanghai, China.
FAU - Zhou, Lili
AU  - Zhou L
AD  - Myeloma and Lymphoma Center, Department of Hematology, Changzheng Hospital, 
      Shanghai, China.
FAU - Zhang, Chunyang
AU  - Zhang C
AD  - Myeloma and Lymphoma Center, Department of Hematology, Changzheng Hospital, 
      Shanghai, China.
FAU - Xi, Hao
AU  - Xi H
AD  - Myeloma and Lymphoma Center, Department of Hematology, Changzheng Hospital, 
      Shanghai, China.
FAU - Li, Rong
AU  - Li R
AD  - Myeloma and Lymphoma Center, Department of Hematology, Changzheng Hospital, 
      Shanghai, China.
FAU - Hou, Jian
AU  - Hou J
AD  - Myeloma and Lymphoma Center, Department of Hematology, Changzheng Hospital, 
      Shanghai, China. Electronic address: houjian167@sohu.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150318
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - 13q deletion syndrome
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chromosome Deletion
MH  - Chromosome Disorders/complications
MH  - Chromosomes, Human, Pair 13
MH  - Cohort Studies
MH  - Female
MH  - *Gene Deletion
MH  - *Genes, Immunoglobulin Heavy Chain
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/complications/*diagnosis/*genetics/mortality
MH  - Prognosis
MH  - Survival Analysis
OTO - NOTNLM
OT  - IGH deletion
OT  - Interphase fluorescence in situ hybridization
OT  - Multiple myeloma
OT  - Prognosis
EDAT- 2015/03/31 06:00
MHDA- 2015/08/04 06:00
CRDT- 2015/03/31 06:00
PHST- 2014/10/16 00:00 [received]
PHST- 2015/02/09 00:00 [revised]
PHST- 2015/02/22 00:00 [accepted]
PHST- 2015/03/31 06:00 [entrez]
PHST- 2015/03/31 06:00 [pubmed]
PHST- 2015/08/04 06:00 [medline]
AID - S0145-2126(15)00067-3 [pii]
AID - 10.1016/j.leukres.2015.02.010 [doi]
PST - ppublish
SO  - Leuk Res. 2015 May;39(5):515-9. doi: 10.1016/j.leukres.2015.02.010. Epub 2015 Mar 
      18.